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Abstract: Objective To determine differences in the characteristics of cancer drugs designated as orphan
drugs by the Food and Drug Administration (FDA) and European Medicines Agency (EMA). Design
and setting Identification of all cancer drugs (initial or supplementary indication) with orphan status
approved by the FDA between 2008–2017 based on publicly accessible reports. The European public
assessment reports (EPAR) was searched to determine whether these FDA-approved drugs were also
approved by the EMA. Main outcome measures Extraction of active ingredient, trade name, approval
date and approved indication from two FDA data sources (Orphan Drug Product Designation Database,
Drugs@FDA) and comparison with the same data from EPAR. Results The FDA approved 135 cancer
drugs with orphan indications that met our inclusion criteria, of which 101 (75%) were also approved
by the EMA. 80/101 (79%) were first approved in the USA. Only 41/101 (41%) also received orphan
designation by the EMA. 33/101 (33%) were approved for biomarker-based indications in the USA,
however, only nine approved cancer drug indications by the EMA were biomarker-derived drugs. 78%
(47/60) of approved cancer drugs that were only approved in the USA with orphan status were indicated
for solid tumours, 22% (13/60) had indications for non-solid tumours. By contrast, out of those approved
cancer drugs that received orphan designation by both agencies, 20% (8/41) were indicated for solid, and
80% (33/41) for non-solid tumours. Conclusions Orphan designation was intended to encourage drug
development for rare conditions. This study shows that the FDA approves more cancer drugs with such
designations compared with the EMA, especially for subgroups of more prevalent cancers. One reason
for the difference could be that the European Union requires demonstration of significant benefit for
drugs that target the same indication as a drug already on the market to earn the orphan designation.
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Strengths and limitations of this study
 ► Our methodological and comparative approach en-
ables to find possible solutions of how the USA could 
adopt useful policies applied in the European Union 
(EU) and thus improve the development of innovative 
cancer drugs.
 ► The inclusion of approved cancer drugs designated 
with orphan status over a time period of 10 years 
enables to detect informative trends in the specif-
ic jurisdiction (USA and EU) as well as meaningful 
comparisons between the jurisdictions.
 ► To date, no study analysed the differences in the 
application of orphan status on cancer drugs by the 
Food and Drug Administration (FDA) and European 
Medicines Agency (EMA).
 ► Our study is restricted to cancer drugs, and so is not 
generalisble to other drug classes.
 ► We did not investigate whether all approved cancer 
drugs with orphan designation by the EMA between 
those same years also received this status by the 
FDA. Therefore, it may be possible that certain can-
cer drugs with orphan designation by the EMA did 
not get this designation by the FDA.
ABSTRACT
Objective To determine differences in the characteristics 
of cancer drugs designated as orphan drugs by the Food 
and Drug Administration (FDA) and European Medicines 
Agency (EMA).
Design and setting Identification of all cancer drugs 
(initial or supplementary indication) with orphan status 
approved by the FDA between 2008–2017 based 
on publicly accessible reports. The European public 
assessment reports (EPAR) was searched to determine 
whether these FDA-approved drugs were also approved by 
the EMA.
Main outcome measures Extraction of active ingredient, 
trade name, approval date and approved indication from 
two FDA data sources (Orphan Drug Product Designation 
Database, Drugs@FDA) and comparison with the same 
data from EPAR.
Results The FDA approved 135 cancer drugs with orphan 
indications that met our inclusion criteria, of which 101 
(75%) were also approved by the EMA. 80/101 (79%) 
were first approved in the USA. Only 41/101 (41%) also 
received orphan designation by the EMA. 33/101 (33%) 
were approved for biomarker-based indications in the USA, 
however, only nine approved cancer drug indications by 
the EMA were biomarker-derived drugs. 78% (47/60) of 
approved cancer drugs that were only approved in the USA 
with orphan status were indicated for solid tumours, 22% 
(13/60) had indications for non-solid tumours. By contrast, 
out of those approved cancer drugs that received orphan 
designation by both agencies, 20% (8/41) were indicated 
for solid, and 80% (33/41) for non-solid tumours.
Conclusions Orphan designation was intended to 
encourage drug development for rare conditions. This 
study shows that the FDA approves more cancer drugs 
with such designations compared with the EMA, especially 
for subgroups of more prevalent cancers. One reason for 
the difference could be that the European Union requires 
demonstration of significant benefit for drugs that target 
the same indication as a drug already on the market to 
earn the orphan designation.
INTRODUCTION
The US Congress passed the Orphan Drug 
Act in 1983 to create incentives for the devel-
opment of drugs for rare diseases that might 
not otherwise be financially viable due to 
small potential patient populations.1–3 Among 
other things, the statutory incentives include 
providing manufacturers with the opportu-
nity to earn special tax breaks for research 
investment and the exclusive right to market 
orphan-designated drugs for 7 years from the 
date of marketing approval.1, 4, 5 Such market 
exclusivity would allow manufacturers to 
charge high prices for their rare disease drug 
product even in the absence of patent protec-
tion and despite limited health gain.5–9
Pharmaceutical companies can apply for 
orphan designation from the Food and 
Drug Administration (FDA) based on either 
showing that the targeted condition affects 
fewer than 200 000 patients annually in the 
USA or showing no reasonable expectation 
that costs of research and development of the 
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sales of the drug in the USA, along with providing a medi-
cally plausible basis for believing that the drug would aid 
in the condition’s treatment, prevention or diagnosis.10 11
In the European Union (EU), the European Medicines 
Agency (EMA) also designates drugs that target rare 
diseases with special status.12 To qualify, a drug must be 
intended for the treatment of a disease that is life-threat-
ening or chronically debilitating with an EU prevalence of 
less than 5 in 10,000, or it must be unlikely that marketing 
of the drug would generate sufficient returns to justify the 
investment needed for its development.13–15 In addition, 
no satisfactory method of treatment of the condition 
concerned is already on the market, or, if such a method 
exists, the new drug must be of significant benefit to those 
affected by the condition.11 Like in the USA, sponsors of 
designated orphan drugs in the EU earn certain incen-
tives, including administrative regulatory fee reductions 
and market exclusivity.11 15 16 Thus, while most prerequi-
sites for orphan disease drug designation between the 
USA and the EU are comparable, the major difference is 
that the EU requires demonstration of significant benefit 
in case the drug targets the same indication as a drug 
already on the market.
Expenditure on cancer drugs dominate pharmaceu-
tical expenditure in developed markets, with worldwide 
sales at $107 billion in 2015, an increase of 11.4% since 
2014.8 17 18 In addition, global spending on orphan-des-
ignated drugs will reach $178 billion per year by 2020, 
much of which will also be drugs for cancer patients.8
To determine whether differences in the design of the 
Orphan Drug Act in the US and EU lead to variations in 
the application of the statutory incentives, we reviewed all 
cancer drugs for which indications have been approved 
with this special status between 2008 and 2017 by the FDA 
and then determined whether these cancer drugs had 
also been approved with the same status by the EMA.
METHODS
We first searched and identified on the FDA’s publicly 
accessible Orphan Drug Product Designation Database 
all cancer drugs with orphan status approved by the FDA 
between 1 January 2008 and 31 December 2017.19 The 
approval could have been for an initial or supplementary 
indication. Cancer drugs with approval for different indi-
cations were counted separately for each cancer indica-
tion. For example, bevacizumab (Avastin) was approved 
with orphan status for, among other things, treatment 
of patients with ovarian cancer, fallopian tube cancer, 
primary peritoneal cancer and glioblastoma. Cancer 
drugs with orphan status that were approved by the FDA 
for benign tumours as well as combined therapies (eg, 
dabrafenib and trametinib (Mekinist)) were not included 
in our analysis. From two FDA data sources—the Orphan 
Drug Product Designation Database and Drugs@FDA—
we extracted the active ingredient, trade name, orphan 
designation, approval date and approved indication.19 20
We then searched on the database of the EMA, the 
European public assessment reports (EPAR), to deter-
mine whether the FDA-approved cancer drugs with 
orphan status in our cohort were also approved by the 
EMA (with or without orphan status) as of 1 August 2018. 
Following the methodology of another study, we assumed 
that the same drug is available both in the EU and USA if 
the active substance, the therapeutic indication and the 
Marketing Authorisation Holder are the same between 
both territories.21 If so, we extracted the same data as 
from the FDA sources.
Descriptive statistics were performed for the recorded 
variables. Trends across time and indications of cancer 
drugs with orphan designation were analysed descrip-
tively and in comparison between the EU and USA.
Patient and public involvement
No patients or members of the public were involved in 
the design and conception of this study.
RESULTS
The FDA approved 135 cancer drug indications with 
orphan drug designations that met our inclusion criteria. 
Among this sample, 101 (75%) were also approved by the 
EMA by 1 August 2018, including drugs with and without 
such a designation by the EMA (see online supplemen-
tary appendix). Two indications were refused market 
approval in the EU: romidepsin (Istodax) was refused for 
treatment of non-Hodgkin’s lymphoma, and pralatrexate 
(Folotyn) for treatment of T-cell lymphoma. Sponsors 
withdrew their market application for four indications, 
including dinutuximab (Unituxin) for treatment of 
neuroblastoma, which was withdrawn due to the inability 
to supply the drug in sufficient quantities for meeting the 
demands, and omacetaxine (Synribo) for treatment of 
myelogenous leukaemia because of inability to address 
the issues identified by the EMA within the timeframe 
allowed.22
Among the 101 cancer indications that were designated 
with orphan drug status by the FDA and also approved by 
the EMA, 46 were approved for first-line therapy while 
55 were indicated for second-line, third-line or fourth-
line therapy. Forty-five were approved for supplementary 
(extended) indications of already-approved drugs. There 
was a substantial increase in designations over time. In the 
USA, two approved cancer drug indications were desig-
nated with orphan status in 2008, while 16 were approved 
in 2016 (figure 1).
Eighty of the 101 approved cancer drug indications 
were first approved in the USA, while market approval 
first took place by the EMA for the other 21. In 81% 
(65/80), approval in one jurisdiction followed less than a 
year after market authorisation in the other jurisdiction. 
For example, nivolumab (Opdivo) was approved in the 
USA in December 2017. Approval by the EMA followed 
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Figure 1 Approved cancer drug indications with orphan 
drug designation by the FDA from 2008 through 2017 that 
were also approved by the EMA (n=101). x-axis, year of 
marketing approval by the FDA; y-axis, number of approved 
cancer indications with orphan drug designation by the FDA.
Figure 2 Numbers of FDA-approved and EMA-approved 
drugs indicated for biomarker-defined orphan cancer 
indications from 2008 through 2017. x-axis, year of marketing 
approval by the FDA and EMA; y-axis, number of approved 
biomarker-derived cancer indications with orphan drug 
designation; blue, approved biomarker-derived cancer 
indications with orphan designation by the FDA; orange, 
approved biomarker-derived cancer indications with orphan 
designation by the EMA.
Among the 101 orphan drug designated approved 
cancer conditions, 40% (40/101) were approved for 
biomarker-derived indications. A biomarker-derived indi-
cation is any drug indication approved based on its effi-
cacy in a subset of a more prevalent disease characterised 
by a particular genetic variant.23 Examples for approved 
biomarker-derived indications in our study are nivolumab 
(Opdivo) for the treatment of BRAF V600 mutated mela-
noma, or ceritinib (Zykadia) for the treatment of ALK 
+non-small cell lung cancer (NSCLC), afatinib (Gilotrif) 
for EGFR mutated NSCLC and osimertinib (Tagrisso) for 
EGFR mutated NSCLC. The number of approved biomark-
er-defined indications with orphan drug designation has 
increased over the past years in the USA (figure 2). Only 
one biomarker-derived cancer indication was approved 
with orphan drug designation in 2008, while eight were 
approved with orphan status in 2017. By contrast, only 
10% (10/101) of approved cancer drug indications by 
the EMA were orphan designated biomarker-defined 
subsets of disease. For example, afatinib (Gilotrif) and 
osimertinib (Tagrisso) got approval in both the USA and 
the EU, however, they only got orphan designation in the 
USA.
Only 41 of the 101 cancer indications with orphan 
designation by the FDA were also designated with orphan 
status at the time of market approval by the EMA. While 
most of the 60 remaining products never received an 
orphan drug designation in the EU, 4 drugs had their 
designations withdrawn by the EMA or the sponsor, 
including olaparib (Lynparza) for treatment of primary 
peritoneal cancer and later treatment of ovarian cancer 
and fallopian tube cancer, as well as bosutinib (Bosulif) 
for treatment of chronic myelogenous leukaemia.
The approved cancer drug indications can be differen-
tiated into solid and non-solid tumours.9 24–26 The majority 
(47/60, 78%) of approved cancer drugs that were only 
approved in the USA with orphan status were indicated 
for solid tumours, while 22% (13/60) of approved 
cancer drugs had indications for non-solid tumours. Most 
frequently approved indications with orphan drug desig-
nation for solid tumours were melanoma (13 indications) 
followed by non-small cell lung cancer (11 indications), 
gastrointestinal cancer (five indications), ovarian cancer 
(three indications), fallopian tube cancer (three indica-
tions) and peritoneal cancer (three indications). Most 
approved cancer indications with orphan designation 
for non-solid tumours by the FDA were chronic myelog-
enous lymphoma (three indications), multiple myeloma 
(two indications), Hodgkin lymphoma (two indications), 
chronic lymphocytic lymphoma (two indications) and 
acute lymphocytic lymphoma (two indications) (figure 3).
By contrast, out of those approved cancer drugs that 
were designated with orphan status by both the FDA and 
the EMA, 20% (8/41) were indicated for solid tumours, 
and 80% (33/41) for non-solid tumours. Thyroid cancer 
(three indications), ovarian cancer (two indications) 
and soft tissue sarcoma (two indications) were the most 
frequent solid tumours approved in both jurisdictions 
with orphan drug status. For non-solid tumours, multiple 
myeloma (eight indications), chronic lymphocytic 
lymphoma (eight indications) and acute lymphocytic 
lymphoma (four indications) were the most frequently 
approved cancer drug indications with orphan designa-
tion (figure 4).
DISCUSSION
This review of cancer drugs newly approved with 
Orphan Drug Act designations by the FDA from 2008 
through 2017 reveals important differences with respect 
to their approvals by the EMA. Less than 50% of cancer 
drugs with orphan designation by the FDA received such 
status in the EMA. Our results are consistent with other 
studies showing that the USA has more orphan drug 
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Figure 3 FDA-approved solid and non-solid tumour 
cancer drug indications with orphan drug designation. ALL, 
acute lymphoblastic leukaemia; CLL, chronic lymphocytic 
lymphoma; CML, chronic myeloid lymphoma; NSCLC, non-
small cell lung cancer.
Figure 4 FDA-approved and EMA-approved solid and 
non-solid tumour cancer drug indications with orphan 
drug designation. ALCL, anaplastic large cell lymphoma; 
ALL, acute lymphoblastic leukaemia; AML, acute myeloid 
lymphoma; CLL, chronic lymphocytic lymphoma; CML, 
chronic myeloid lymphoma; SLL, small lymphocytic 
lymphoma; cut. T-cell lymphoma, cutaneous T-cell lymphoma.
drugs compared with the EU.21 27 28 Drugs that targeted 
biomarker-defined subsets of common cancer types 
often received orphan status in the USA, but did not get 
similar status in the EU.
The number of drugs targeting subpopulations of 
specific cancers has increased over the last decade 
with a simultaneous increase in the number of orphan 
designation by the FDA for drugs indicated for cancers 
defined as biomarker-based subsets of more common 
cancers.23 29–31 However, it is interesting to note that the 
EMA does not follow this pattern (figure 2). Among the 
101 orphan-designated drugs from 2008 through 2017, 
40% (40/101) were approved for indications defined 
in part by biomarkers by the FDA, as compared with 
only 10% (10/101) by the EMA. For example, the FDA 
approved alectinib (Alecensa) and ceritinib (Zykadia) to 
treat ALK+non-small cell lung cancer, crizotinib (Xalkori) 
to treat ROS1-positive non-small cell lung cancer and 
dabrafenib (Tafinlar) to treat BRAF V600E mutated meta-
static melanoma.23 32 However, none of these drugs were 
designated with orphan status by the EMA (see figure 4 
and online supplementary appendix).
Drugs receiving designations in both settings were 
more likely to focus on truly rare cancers, such as multiple 
myeloma or follicular lymphoma. In the EU, the use of 
biomarkers to identify a subset of patients for whom the 
drug can be used appears to generally not be accepted 
as a basis for receiving orphan designation.33 34 However, 
biomarker-derived cancer drugs can still get orphan 
status in the EU if, among other things, it is unlikely that 
marketing of the drug would generate sufficient returns 
to justify the investment needed for its development 
and the sponsor provides scientific evidence that the 
activity of the product would not be shown in the larger 
population.35
One important reason for the different application 
of ‘orphan status’ in the USA and the EU could be the 
different legal prerequisites for orphan designation. 
The demonstration of ‘significant benefit’ is mandatory 
for drugs to be designated with orphan status by the 
EMA compared with those drugs already on the market 
targeting the same disease.15 34 36 ‘Significant benefit’ 
means that a drug has a clinically relevant advantage or 
makes a major contribution to patients’ care, compared 
with existing drugs already on the market that target the 
same condition.33 37 Significant benefit is a higher stan-
dard than the positive benefit-risk assessment that must be 
demonstrated by the sponsor in the marketing approval 
process, which does not involve an obligation to show that 
such a drug is more beneficial than all other methods 
for treating the same condition.19 Significant benefit is 
required at the time of orphan designation, when it can 
be supported by preclinical studies, and at the time of 
marketing approval, when clinical data are needed.36 Our 
study has shown that a few drugs had their orphan drug 
designations withdrawn during the marketing approval 
process, including olaparib (Lynparza) for treatment of 
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tube cancer, and bosutinib (Bosulif) for treatment of 
chronic myelogenous leukaemia in the EU.
Adding a prerequisite of ‘significant benefit’ to main-
tain orphan drug designation at the time of FDA approval 
in the USA could help prevent non-first-in-class drugs 
targeting rare diseases from earning the same incentives 
as a presumptively more clinically important first-in-class 
drug for a rare disease. If the second-to-market product 
offered significant benefits over available treatments, it 
would get to keep its designation.
Strengths and weaknesses of this study
Our study reveals important new differences of approved 
cancer drugs with orphan designation between the USA 
and the EU allowing policy implications for the USA in 
order to ensure that only truly rare diseases will be desig-
nated orphan status for which research investment is 
limited.
This study has certain limitations. It was restricted to 
cancer drugs, and so is not generalisable to other drug 
classes. Also, we did not investigate whether all approved 
cancer drugs with orphan designation by the EMA 
between those same years also received orphan status by 
the FDA. Therefore, it may be possible that certain cancer 
drugs with orphan designation by the EMA did not get 
orphan designation by the FDA.
CONCLUSION
The Orphan Drug Act in the USA was intended to 
encourage drug development for rare conditions with 
unmet medical needs. We found that the FDA approves 
more drugs with such designations for cancer subgroups 
compared with the EMA. The statute could be revised to 
ensure it applies to truly rare diseases for which research 
investment is limited. Other changes to the US Orphan 
Drug Act could include assessing whether there is ‘signifi-
cant benefit’ at the time of approval if treatments already 
exist for a disease targeted by a new drug. Implementa-
tion of these reforms could help to improve the devel-
opment of innovative cancer drugs and by encouraging 
more resources to be directed to rare cancers that lack 
effective treatments.
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